Phase 1 Dose-Escalation Study With LEC/Chtnt-3 and Toceranib Phosphate (Palladia) in Dogs With Spontaneous Malignancies

Journal of Cancer Science & Therapy
doi 10.4172/1948-5956.1000343
Full Text
Abstract

Available in full text

Date
Authors
Publisher

OMICS Publishing Group

Related search

A Phase 1, Open-Label, Dose Escalation Study of Intravenous Paricalcitol in Combination With Gemcitabine in Patients With Advanced Malignancies

Cancer
Cancer ResearchOncology
2018English

Phase I Dose-Escalation Study of Onartuzumab as a Single Agent and in Combination With Bevacizumab in Patients With Advanced Solid Malignancies

Clinical Cancer Research
Cancer ResearchOncology
2014English

Ono-4059 (Gs-4059), a Next Generation BTK Inhibitor, Monotherapy in Patients With B-Cell Malignancies in the Japanese Phase 1, Dose-Escalation Study

Hematological Oncology
MedicineCancer ResearchOncologyHematology
2017English

Phase 1 Dose-Escalation Study of Single-Agent Veliparib in Japanese Patients With Advanced Solid Tumors

Cancer Science
Cancer ResearchMedicineOncology
2017English

A First-In-Human, Phase I, Dose-Escalation Study of TAK-117, a Selective PI3Kα Isoform Inhibitor, in Patients With Advanced Solid Malignancies

Clinical Cancer Research
Cancer ResearchOncology
2017English

Assessment of Postoperative Adjuvant Treatment Using Toceranib Phosphate Against Adenocarcinoma in Dogs

Journal of Veterinary Internal Medicine
MedicineVeterinary
2020English

A Phase 1b/2, Open-Label, Dose-Escalation, and Dose-Confirmation Study of Eribulin Mesilate in Combination With Capecitabine

British Journal of Cancer
Cancer ResearchOncology
2019English

Tanespimycin Monotherapy in Relapsed Multiple Myeloma: Results of a Phase 1 Dose-Escalation Study

British Journal of Haematology
Hematology
2010English

Phase I Dose-Escalation Study and Biomarker Analysis of E7080 in Patients With Advanced Solid Tumors

Clinical Cancer Research
Cancer ResearchOncology
2011English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy